CN101904847A - Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs - Google Patents
Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs Download PDFInfo
- Publication number
- CN101904847A CN101904847A CN2009100851169A CN200910085116A CN101904847A CN 101904847 A CN101904847 A CN 101904847A CN 2009100851169 A CN2009100851169 A CN 2009100851169A CN 200910085116 A CN200910085116 A CN 200910085116A CN 101904847 A CN101904847 A CN 101904847A
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- blood pressure
- valsartan
- amlodipine nicotinate
- sartans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of common amlodipine nicotinate capable of improving the blood pressure reduction effect of amlodipine and a preparation method, wherein the common amlodipine nicotinate can be independently applied or can be mixed with statin pressure-reducing drugs or pharmaceutical salts thereof. The composition can be used for treating patients (including human beings) suffered from angina, and/or with dangerous heat symptoms in the process of combing the high blood pressure treatment and improving the pharmacologic efficiency of the traditional like medicines.
Description
Technical field
The present invention relates to a kind of application that can improve the public salt (-)-amlodipine nicotinate of amlodipine blood pressure lowering effect, and the compositions that comprises this novel public salt, comprising: 1) (-)-amlodipine nicotinate; 2) application of the pharmaceutical composition of husky smooth hypotensor thing or its officinal salt, and preparation method.Above-mentioned composition can be used to treat the patient's (comprising the mankind) who suffers from angina pectoris and/or complicated hypertension and treatment and have the cardiac risk symptom, improves existing similar medicine pharmacology usefulness.
Background technology
Amlodipine and relevant dihydropyridine compound are disclosed in United States Patent (USP) 4,572,909, and this article is hereby incorporated by reference, and they are effective anti-ischemic and antihypertensive.United States Patent (USP) 4,879,303, this article is hereby incorporated by reference, and discloses amlodipine sulfonate (being also referred to as the sulfonic acid amlodipine).Amlodipine sulfonate is sold with " Norvasc " trade name at present.Amlodipine sulfonate and amlodipine and other pharmaceutically acceptable acid addition salts can be used as antihypertensive and anti-ischemic.Chinese patent application 00,124,812 disclose amlodipine niacin, and this article is hereby incorporated by reference.
Nicotinic acid has another name called vitamin B3, for having C
5H
4NCO
2The organic compound of H molecular formula.Nicotinic acid is the derivant of pyridine, is colourless water-soluble solid, is characterised in that 3 of pyridines to have a carboxylic acid.Nicotinic acid changes nicotiamide in vivo into, and both have identical vitamin function.Nicotinic acid is the precursor of NADK, NAD and NADP, and the latter plays basic metabolism in living cells, and DNA repairs and produces steroid hormone the adrenal gland.The nicotinic acid physicochemical properties are stable, and are survivable under acid, alkali, oxygen, light or heating condition.
The commodity Norvasc by name that Amlodipine Besylate Tablet is current.Chinese patent application 00,124,812 disclose (-)-amlodipine nicotinate (being also referred to as amlodipine niacin), and this article is hereby incorporated by reference.Amlodipine niacin is the same with nicotinic acid to have excellent stability.Compare with Amlodipine Besylate Tablet, amlodipine niacin has the light stability and the heat stability of improvement, and more excellent physicochemical properties, as dissolubility.
Hypertension is a cause of disease and the very complicated syndrome of pathogenesis, existing nerve also has the unusual of body fluid aspect, and often have influence on the 26S Proteasome Structure and Function of each organ of body, system, the patient most simultaneously with other disease after one's own heart, brain, kidney or angiopathy, insulin sensitivity reduction, dyslipidemia etc.Therefore, share the different depressor of mechanism of action and often can strengthen therapeutic effect, look after the different links in the hypertension incidence mechanism simultaneously, make multiple risk factor or and deposit disease and obtain Optimal Control, more help the protection of hypertension target organ 26S Proteasome Structure and Function, further reduce the incidence rate of cardiovascular event; Secondly, because when forming immobilised compound, the dosage of each single medicine all has minimizing, thereby the incidence rate of drug side effect reduces; About medical expense, reduce when using separately owing to used drug dose ratio, not only can not increase, may descend on the contrary, feasible benefit/expense ratio for the treatment of is significantly improved.In addition, coupling can be administered once and need not be administered twice or repeatedly, so patient's treatment compliance increases greatly, and quality of life also just obviously improves.The fixed compound preparation of antihypertensive low dose not only can be used as the two wires medicine, also can be used as a line medicine and is used for hypertensive treatment, and is all the more so when especially the patient has other complication to exist simultaneously.Chinese patent application 99,809,776 and division 200,510,072,738 pharmaceutical composition of Amlodipine Besylate Tablet and valsartan and the method for suffering from the patient of hypertension or heart failure with these combination treatments have been described.Chinese patent application 200,510,098,619 describes and to contain the compositions that comprises Amlodipine Besylate Tablet and angiotensin-ii receptor inhibitor and to hypertension with exist the individuality of cardiac risk symptom to comprise the method that the people treats.
Summary of the invention
The inventor has found that by going deep into pharmacological research the usefulness of the public salt blood pressure lowering of amlodipine nicotinic acid is higher than existing Amlodipine, and then finds, the blood pressure lowering usefulness of the blood pressure lowering compound recipe of forming with this public salt is better than the corresponding former compound recipe that grinds.
Thereby, the invention provides the public salt of amlodipine nicotinic acid and have application in the medicine of better antihypertensive effect in preparation.
Described antihypertensive drugs can be folk prescription or the compound recipe that comprises (-)-amlodipine nicotinate, comprise also in the compound recipe that other are with the pressing thing, preferred sartans, preferred especially Losartan Potassium, irbesartan, Candesartan, Tasosartan, eprosartan, telmisartan, valsartan or olmesartan medoxomil.
But compositions described herein self is applied to people patient, or itself and other active component, or suitable carriers or mixed with excipients become to be used for therapeutic alliance in the pharmaceutical compositions.The preparation of the application's chemical compound and the technology of using are found in " Remington ' s pharmaceutical " Mack Publishing Co., Easton, PA, 18
ThEdition, 1990.
That suitable route of administration can comprise is oral, rectum, stride mucosa or enteral is used.Perhaps, can the part rather than the mode administered compound of whole body, for example, with the form of depot or slow releasing preparation.In addition, can drug target delivery system drug administration, for example, with the liposome form of tissue specificity antibody sandwich.Organ will be with liposome as target and carry out selectivity and absorb.
Can produce pharmaceutical compositions of the present invention in known manner, for example, by traditional mixing, dissolving, granulation, one-tenth ingot, grinding, emulsifying, encapsulation or tabletting method.
Therefore, pharmaceutical compositions used according to the invention can be made in a conventional manner, and this mode uses one or more physiology to go up acceptable carrier, and these carriers comprise pharmaceutically acceptable excipient and the adjuvant of being convenient to reactive compound is processed into preparation.Appropriate formulation depends on the route of administration of selection.Can use this area any suitable know technology, carrier and excipient, described in above-mentioned Remington ' s pharmacy.
For Orally administered, can be by reactive compound and pharmaceutically suitable carrier well known in the art combination be easily made compositions.These carriers can be made The compounds of this invention tablet, pill, powder agent, lozenge, capsule, gel, syrup, unguentum, suspension, cachet and suppository etc., are used for the patient and orally use.The pharmaceutical formulations that orally uses can be by mixing acquisitions with one or more solid excipient with pharmaceutical compositions of the present invention, chooses the mixture that adds when needed after the proper supplementary material generation wantonly and grinds, and handle that particulate mixture gets tablet or lozenge is examined.For this purpose, available spissated sugar juice, it can be chosen wantonly and comprise arabic gum, Talcum, polyvinylpyrrolidone, carbopol gel, Polyethylene Glycol and/or titanium dioxide, lacquer solution and appropriate organic solvent or solvent mixture.Dyestuff or pigment can be added in tablet or the lozenge coating combination with identification or qualitative different activities chemical compound dosage.
The pharmaceutical formulations that can orally use comprises plug-in type capsule of being made by gelatin and sealing soft capsule and the plasticizer of being made by gelatin, as glycerol or sorbitol.The plug-in type capsule can comprise active component, this composition and filler, and as lactose, binding agent is as starch and/or lubricant, as Talcum or magnesium stearate and optional stabilizer mixing.In soft capsule, can or be suspended in suitable fluid with the reactive compound dissolving, in fatty oil, liquid paraffin or liquid macrogol.In addition, can add stabilizing agent.All Orally administered preparations should be and are suitable for Orally administered dosage form.
For oral administration, compositions can adopt tablet or the lozenge form of making in a conventional manner.
Chemical compound also can be made into the rectum compositions, as suppository or enema,retention, for example, comprises traditional suppository base, as cupu oil or other glyceride.
Except that previous formulations, chemical compound also can be made into depot formulation.These durative action preparations can pass through to implant, for example, and subcutaneous or intramuscular.Therefore, for example, polymerization that chemical compound can be suitable or hydrophobic material (for example, the Emulsion in the suitable oil) or ion exchange resin, or slightly soluble derivant, for example, the preparation of slightly soluble salt.
In powder agent, carrier is finely divided solid, it be with the mixture of finely divided active component in.
Perhaps, can use other delivery system of hydrophobic pharmaceutical compound.Liposome and Emulsion are to send the medium of dewatering medicament or the well-known example of carrier.Also can use some organic solvent, as dimethyl sulfoxide, although have bigger toxicity usually.In addition, can use lasting delivery systme to send chemical compound, as comprise the polymeric semi permeability substrate of solid hydrophobic of medicine.Set up the material of various lasting releases, and be well known to those skilled in the art.Depend on its chemical property, the capsule that continues to discharge can discharge several weeks of chemical compound, nearly more than 100 day.Depend on the chemical property and the biological stability of treatment reagent, can use other strategy of stabilize proteins.
The chemical compound lot that is used for pharmaceutical compositions of the present invention can be the salt with pharmaceutically acceptable equilibrium ion.Officinal salt can be many acid form, these acid include, but are not limited to hydrochloric acid, sulphuric acid, acetic acid, lactic acid, tartaric acid, malic acid, succinic acid etc.The dissolubility of salt in aqueous or other protonic solvent is tending towards greater than corresponding free acid or alkali form.
The pharmaceutical compositions that is suitable for the present invention's use comprises some compositions, wherein comprises effective amount of actives, to realize its intended purposes.More specifically, effectively therapeutic dose refers to that chemical compound effectively prevents, alleviates or improve the amount of disease symptoms or extended treatment patient survival.Effectively the definite of therapeutic dose is positioned within those skilled in the art's the limit of power well, especially according to provided herein disclosing in detail.
Pharmaceutical preparation preferably contains the unit dosage form of the active component of appropriate amount.Unit dosage form can be a packaged preparation, and packing contains preparation dispersion amount, for example powder agent in parcel tablet, capsule and bottle or the ampoule.Also have, unit dosage form itself can be capsule, tablet, cachet or lozenge, and perhaps it can be the packaged form of proper number.
The amount of amlodipine niacin is 0.1-100mg, preferred 1-25mg, more preferably 2.5-10mg.
Described " husky smooth class " chemical compound refers to irbesartan, telmisartan, valsartan, losartan, Candesartan or its officinal salt, and its, consumption was 1-500mg, more preferably 10-320mg every day.Pharmaceutically suitable carrier or diluent such as above-mentioned or described in Remington ' s pharmacy.
One skilled in the art can look species, age and the individual instances of object and the dosage that administering mode obtains the necessary active component of expected effect.In normal conditions, in case of oral administration, be for the patient of the about 70kg of body weight, the oral roughly daily dose of amlodipine niacin is-25mg preferred 2.5-10mg.
Pharmaceutical composition of the present invention and method all are suitable as mammal, mammal is optional from mice, rat, rabbit, Cavia porcellus, Canis familiaris L., cat, sheep, goat, milch cow, primates, as monkey, orangutan and ape and people, particularly to human therapy, angina pectoris, atherosclerosis hypertension and hyperlipemia complication occur with being characterised in that.
In addition, because the appearance of these diseases and symptom and cardiopathic generation and disadvantageous heart is closely related, these combinations and method rely on their effects as antianginal and hyperlipidemia, are useful in cardiac risk is handled.
Term used herein " cardiac risk " meaning is that the patient suffers disadvantageous heart sympton, for example, and myocardial infarction, asystole, heart failure, myocardial ischemia.The Framingham that utilization provides above is dangerous, and equation calculates cardiac risk.Term " cardiac risk management " meaning is that the danger of following disadvantageous heart sympton is reduced in fact.
Other dosage that the following dosage of mentioning in description and claims and other place are mentioned is to be the patient of about 65kg-70kg at weight average.The disease historical according to patient's medication and the experimenter exists, diabetes for example, the technical staff can easily determine the dosage of the experimenter needs of body weight outside 65kg-70kg.All dosage of mentioning in description and claims is daily dose.
Following non-limiting example describes the application of pharmaceutical composition of the present invention in detail.
Embodiment
Embodiment 1
The contrast experiment of the blood pressure lowering pharmacology effect of amlodipine niacin, Amlodipine Besylate Tablet, valsartan/amlodipine niacin sheet and valsartan/amlodipine besylate tablets
1 experiment purpose
This experiment comparative study amlodipine niacin, Amlodipine Besylate Tablet, amlodipine niacin (5mg, in amlodipine base, down together)/valsartan (80mg) and of the influence of Amlodipine Besylate Tablet (5mg)/valsartan (80mg) to spontaneous hypertensive rat (SHR) blood pressure.
The self-control of material amlodipine niacin, Amlodipine Besylate Tablet is available from hammer pharmceutical S.P.A (lot number: AB034K00), valsartan is available from Zhejiang Xin Saike Pharmaceutical, and Amlodipine Besylate Tablet/valsartan compound recipe is for preparing according to the method that relates in the patent of mentioning in the background technology.SHR male and female dual-purpose, body weight 250～280g is provided by Military Medical Science Institute zoopery center.RBP20 type rat blood pressure meter (Chinese-Japanese Friendship Clinic Medical Inst).
2 experimental designs and process
Learn from else's experience 50 of qualified SHR of screening are divided into 5 groups at random, i.e. blank group, amlodipine niacin, Amlodipine Besylate Tablet, amlodipine niacin/valsartan group, Amlodipine Besylate Tablet/valsartan group, 10 every group.Administration the previous day, take blood pressure with RBP20 type rat blood pressure instrumentation, as numerical value before the medicine.Irritate stomach once with 1/10 dose intensity every day, and the blank group is irritated stomach once with the isometric(al) normal saline, continuous irrigation stomach 17d every day.Each treated animal respectively at medicine after 1,3,5,7,9,11,13,15 and 17d, 1h is with the clear-headed rat blood pressure of RBP20 type rat blood pressure instrumentation amount after administration.After drug withdrawal, measure blood pressure and heart rate on the 8th day again, carry out statistical procedures at last.
3 results
Behind rat oral gavage amlodipine niacin, Amlodipine Besylate Tablet, amlodipine niacin/valsartan, Amlodipine Besylate Tablet/valsartan, blood pressure all promptly descended rapidly in first day, after this blood pressure keeps more stable state always, amlodipine niacin/valsartan group reaches the peak again from 13d, and the amlodipine niacin group also reaches the peak in 11d relatively certainly, and it is stable that Amlodipine Besylate Tablet group and Amlodipine Besylate Tablet/valsartan group keeps.5 contrast groups are compared, the effect of amlodipine niacin after the administration/valsartan blood pressure lowering best (P＜0.05), Amlodipine Besylate Tablet/valsartan takes second place, and is respectively amlodipine niacin, Amlodipine Besylate Tablet group then, after 1 week of drug withdrawal, blood pressure recovers normal during 25d.The results are shown in Table 1.
The comparative study that the various combinations of table 1 influence the SHR blood pressure (x ± s, p/kPa)
Claims (9)
1. the public salt of amlodipine nicotinic acid has application in the medicine of better antihypertensive effect in preparation.
2. antihypertensive drugs in the claim 1 is characterised in that only to comprise (-)-amlodipine nicotinate.
3. the antihypertensive drugs in the claim 1 and 2 is characterised in that except that comprising (-)-amlodipine nicotinate, also comprises other antihypertensive drugs.
4. other antihypertensive drugs in the claim 3 comprise husky smooth hypotensor thing.
5. the sartans in the claim 4 comprises Losartan Potassium, irbesartan, Candesartan, Tasosartan, eprosartan, telmisartan, valsartan or olmesartan medoxomil.
6. the sartans among the claim 4-5 is a valsartan.
7. the sartans among the claim 4-6 is a telmisartan.
8. the sartans among the claim 4-7 is an olmesartan medoxomil.
9. the sartans among the claim 4-8 is an irbesartan.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100851169A CN101904847A (en) | 2009-06-02 | 2009-06-02 | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100851169A CN101904847A (en) | 2009-06-02 | 2009-06-02 | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101904847A true CN101904847A (en) | 2010-12-08 |
Family
ID=43260535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100851169A Pending CN101904847A (en) | 2009-06-02 | 2009-06-02 | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101904847A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106551932A (en) * | 2016-11-06 | 2017-04-05 | 成都先先先生物科技有限公司 | A kind of antihypertensive drugs compound preparation of better tolerance |
-
2009
- 2009-06-02 CN CN2009100851169A patent/CN101904847A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106551932A (en) * | 2016-11-06 | 2017-04-05 | 成都先先先生物科技有限公司 | A kind of antihypertensive drugs compound preparation of better tolerance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9107837B2 (en) | Sustained release formulation of naltrexone | |
| AU2006257947B2 (en) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(S)-carbonitrile formulation | |
| EP2413931B1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same | |
| CN104220068B (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| WO2015071841A1 (en) | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
| CN101347427A (en) | Compound of losartan compound or its medical salt and calcium channel blocker or its medical salt | |
| EP2061448B1 (en) | Sustained release formulation of naltrexone | |
| CN101653440B (en) | Treatment composition containing amlodipine series salt and pril medicament | |
| TW202200145A (en) | Acalabrutinib maleate dosage forms | |
| CN101468002A (en) | Therapeutic composition containing amlodipine salt and losartan medicine | |
| CN103172576B (en) | The malate acid addition salt of Gefitinib and Synthesis and applications thereof | |
| CN103006648A (en) | Maleic acid levorotation amlodipine drug active pharmaceutical composition and preparation method thereof | |
| CN101904847A (en) | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs | |
| CN102836161A (en) | Medicament compound preparation formed by mixing olmesartan medoxomil with benzene sulfonic acid amlodipine and hydrochlorothiazide | |
| CN101433536A (en) | Therapeutic compositions containing amlodipine niacin and losartan medicament | |
| WO2008148359A1 (en) | The therapeutic uses of imidazol-5-carboxylic acid derivatives | |
| CN102058591A (en) | Levamlodipine and telmisartan compound preparation | |
| CN101904846A (en) | Amlodipine nicotinate with synergetic blood pressure reducing function and treatment composition thereof with Benazapril medicament | |
| CN101904845A (en) | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs | |
| CN1223338C (en) | Cetirizine hydrochloride gel | |
| CN101313907A (en) | Medicament composition for treating hyperpiesis | |
| CN101756929A (en) | Pharmaceutical preparation containing isosorbide mononitrate | |
| CN104173336B (en) | Application of the levo-oxiracetam in prevention or treatment cognition dysfunction medicine is prepared | |
| CN101569623B (en) | Pharmaceutical composition of l-amlodipine and benazepril | |
| CN101229156B (en) | Medicine composition used for cardiovascular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101208 |